STARCOIN GROUP(00399) signed a memorandum of understanding with Supernova and Scaling Lab.

STARCOIN GROUP (00399) announced that on October 16, 2025, the company has entered into two memoranda of understanding: the company has signed the first memorandum of understanding with Supernova, concerning the intention to establish a framework for cooperation between the company and Supernova to develop and manage blockchain-based systems and related token issuance in accordance with applicable US laws and regulations; and to act as the designated representative for Supernova in the collaborative project on AQP functional water technology and relevant biotechnology owned by Supernova. The company has also signed the second memorandum of understanding with Scaling Lab., concerning the intention to cooperate on scientific research related to the epidemiology and physiology of cardiovascular diseases and their risk factors, especially diabetes and its treatment methods (excluding insulin); and further research on aquaporins (AQP) and water and health-related topics. Supernova focuses on commercializing life science technologies that promote health and longevity. Its core product, AQP functional water, is based on Nobel Prize-winning research on water channel proteins, aiming to enhance cell hydration, metabolism, and immune response through optimized water structure at the molecular level. Scaling Lab. is operated by Dr. Hunter Young at the Johns Hopkins University School of Medicine. The company is an investment holding company, with its subsidiaries primarily engaged in the trade of beauty equipment and products in Hong Kong, as well as the research and commercialization of oral insulin products. The company is actively exploring new business opportunities to diversify its revenue sources and implementing strategic plans to enhance performance. The company plans to expand its business into blockchain technology and enter the digital innovation industry. The signing of the first memorandum of understanding indicates the company's commitment to entering the digital innovation industry through potential cooperation with Supernova for the development of this new business division. Regarding the second memorandum of understanding, the company intends to leverage Scaling Lab.'s research capabilities to strengthen the business division focused on diabetes solutions research and support the strategic goal of exploring new business opportunities for the group. The company anticipates long-term cooperation with Supernova and Scaling Lab., which will not only diversify the group's business but also provide new revenue growth opportunities for the group.